Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 18/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8466620 | 0.99 | EBP (0.58) | EBPSIGMAR1ESR1 | |
| SCHEMBL8468620 | 0.85 | EBP (0.41) | EBPSIGMAR1ESR1 | |
| SCHEMBL8466831 | 0.81 | MPO (0.46) | EBPSIGMAR1 | |
| SCHEMBL11821605 | 0.79 | ESR1 (0.72) | EBPSIGMAR1ESR1 | |
| Hydrochloric Acid SCHEMBL8466618 | 0.79 | SIGMAR1 (0.58) | EBPSIGMAR1ESR1 | |
| SCHEMBL13109358 | 0.75 | EBP (0.74) | EBPSIGMAR1ESR1 | |
| SCHEMBL2817611 | 0.75 | ESR1 (0.86) | EBPSIGMAR1ESR1 | |
| Nafoxidine SCHEMBL10563464 | 0.75 | EBP (1.00) | EBPSIGMAR1ESR1 | |
| Nafoxidine SCHEMBL29494604 | 0.75 | EBP (1.00) | EBPSIGMAR1ESR1 | |
| Nafoxidine SCHEMBL153125 | 0.75 | EBP (1.00) | EBPSIGMAR1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5719136-A | Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | claimed |
| EP-3515424-A1 | ANTIESTROGENS AND/OR AROMATASE INHIBITORS FOR USE IN TREATING OBESITY AND RELATED SYMPTOMS | Repros Therapeutics Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018058032-A1 | ANTIESTROGENS AND/OR AROMATASE INHIBITORS FOR USE IN TREATING OBESITY AND RELATED SYMPTOMS | REPROS THERAPEUTICS INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| EP-2819676-A1 | COMBINATION THERAPY FOR TREATING ANDROGEN DEFICIENCY | Repros Therapeutics Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130832-A1 | COMBINATION THERAPY FOR TREATING ANDROGEN DEFICIENCY | REPROS THERAPEUTICS INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-2211848-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | Repros Therapeutics Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009051908-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2009-04-23 | — | — | WO | disclosed |